HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Sørbye, Sveinung Wergeland ^a   Arbyn, Marc ^b   Fismen, Silje ^a   Gutteberg, Tore Jarl ^a,c   Mortensen, Elin Synnøve ^a,c  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC SCREENING; HUMAN; HUMAN PAPILLOMAVIRUS E6 GENE; HUMAN PAPILLOMAVIRUS E7 GENE; HUMAN TISSUE; HYSTERECTOMY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PREDICTIVE VALUE; REPEAT PROCEDURE; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE; WOMEN'S HEALTH; CANCER GRADING; COMPARATIVE STUDY; CYTOLOGY; EARLY DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; UTERINE CERVIX; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADULT; AGED; CERVIX UTERI; COLPOSCOPY; CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RNA, MESSENGER; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 84857072728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026022     Document Type: Article

References (41)

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, et al. (2011) Worldwide burden of cervical cancer in 2008. Ann Oncol.
2. Bray F, Grimsrud TK, Haldorsen T, Johannesen TB, Johansen A, et al. (2010) Cancer in Norway 2008- Cancer incidence, mortality, survival and prevalence in Norway. The Cancer Registry of Norway.
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2007) Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 90: 1-636.
4. Nygård JF, Skare GB, Thoresen SO, (2002) The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 9: 86-91.
5. Johansen BK, Skare GB, Haldorsen T, Eriksen T, Waage R, et al. (2009) The Norwegian cervical cancer screening programme- Annual report 2008. The Cancer Registry of Norway.
6. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, et al. (2010) European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann Oncol 21: 448-458.
7. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, et al. (2008) European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 19: 342-354.
8. Sorbye SW, Fismen S, Gutteberg T, Mortensen ES, (2010) Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 5 (9): e12724.
9. Desai M, Hadden P, Kitchener H, Martin-Hirsch P, Prendiville W, et al. (2010) Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme. NHSCSP Publication No 20 May.
10. Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, et al. (2010) Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol 203: 321-326.
11. Massad LS, Jeronimo J, Katki HA, Schiffman M, (2009) The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 13: 137-144.
12. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, (2010) HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 169: 219-222.
13. Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, et al. (2009) Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 47: 3895-3901.
14. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, et al. (2005) DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 97: 908-915.
15. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, et al. (2005) Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14: 367-372.
16. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, et al. (2005) Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 114: 973-976.
17. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, et al. (2008) Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17: 3033-3042.
18. Trope A, Sjoborg K, Eskild A, Cuschieri K, Eriksen T, et al. (2009) Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol 47: 2458-2464.
19. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, et al. (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337: a1284.
20. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, et al. (2006) Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367: 489-498.
21. Sørbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES, (2011) Triage of Women with Low-Grade Cervical Lesions- HPV mRNA Testing versus Repeat Cytology. PLoS ONE 6 (8): e24083.
22. Richart RM, (1973) Cervical intraepithelial neoplasia. Pathol Annu 8: 301-328.
23. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, et al. (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103: 368-383.
24. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
25. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-1056.
26. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, et al. (2010) Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 48: 2779-2785.
27. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, et al. (2004) Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96: 280-293.
28. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J, (2005) Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 (3 Suppl 1): S7-11.
29. Bjerre P, Silfverdal L, Dillner L, Hagmar B, Edvardsson H, et al. (2008) A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. Am J Obstet Gynecol 199: 24-27.
30. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johansson B, (2009) Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer 101: 511-517.
31. Dillner L, Kemetli L, Elfgren K, Bogdanovic G, Andersson P, et al. (2011) Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities. Int J Cancer 129: 151-9.
32. The ASCUS-LSIL Triage Study (ALTS) Group (2003) Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. AJOG 188: 1383-1392.
33. The ASCUS-LSIL Triage Study (ALTS) Group (2003) A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. AJOG 188: 1393-1400.
34. van Oortmarssen GJ, Habbema JD, (1991) Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 64: 559-565.
35. Ang C, Mukhopadhyay A, Burnley C, Faulkner K, Cross PA, et al. (2011) Histological recurrence and depth of loop treatment of the cervix in women of reproductive age: incomplete excision versus adverse pregnancy outcome. BJOG 118: 685-92.
36. Paraskevaidis E, Kalantaridou SN, Paschopoulos M, Zikopoulos K, Diakomanolis E, et al. (2003) Factors affecting outcome after incomplete excision of cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 24: 541-3.
37. Arbyn M, Simoens C, Goffin F, Noehr B, Bruinsma F, (2011) Treatment of cervical cancer precursors: influence of age, completeness of excision and cone depth on therapeutic failure, and on adverse obstetric outcomes. BJOG 118: 1274-5.
38. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, et al. (2011) Sensitivity, specificity and clinical value of HPV E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 49: 2643-50.
39. Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE, (2008) Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ 337: a1343.
40. Sjøborg KD, Vistad I, Myhr SS, Svenningsen R, Herzog C, et al. (2007) Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand 86: 423-428.
41. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, et al. (2005) A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191: 1808-1816.